Clinical Trial Update: Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Frexalimab (SAR441344) for systemic lupus erythematosus, highlighting ongoing assessment of efficacy and safety and current tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Frexalimab (SAR441344)

Snippet

Sponsor: Sanofi | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: ACTIVE_NOT_RECRUITING